Background: Expression of p16 is increased in a number of malignancies, including
| INTRODUCTION
African American (AA) men have a significantly higher incidence of prostate cancer (PCa) compared with European American (EA) men and are twice as likely to die from PCa compared with EA men. 1 Since AA men account for a significant fraction of all PCa related deaths in the United States, it is important to understand the increased mortality to optimize prevention and treatment strategies for this higher risk group of men. Data from autopsy studies demonstrate a higher incidence of high-grade prostate intraepithelial neoplasia and PCa in AA men when compared with age-adjusted EA men. AA patients exhibit greater tumor volumes in comparison to similarly staged EA patients 2, 3 Several studies have evaluated differential expression of specific proteins including epidermal growth factor receptor, the androgen receptor (AR), cav-1, and others among AA and EA cohorts. 4, 5 A number of studies have compared gene expression in AA and EA PCa using large scale expression microarrays 6-9 including a study from our group. 10 Other studies have focused on a smaller set of preselected genes. [11] [12] [13] Of particular interest is the fact that the TMPRSS2/ERG (T/E) fusion gene is much less frequent in AA PCa. [12] [13] [14] [15] [16] [17] These studies all indicate differential gene expression between AA and EA PCa and point to the fact that AA PCa is biologically distinct in many ways from EA PCa.
The p16 protein negatively regulates the cell cycle by inhibiting cyclin-dependent kinase 4 (CDK4) and CDK6 interaction with cyclin D1. Increased p16 results in decreased retinoblastoma (Rb) protein phosphorylation preventing cell cycle progression from G1 to S. 18, 19 p16 expression is lost in a variety of malignancies including bladder, pancreatic, colorectal, and lung carcinomas and melanomas. 18, 19 Via feedback mechanisms, p16 protein is increased in a number of neoplasms in which the Rb protein is inactivated. In neoplasms arising from human papillomavirus (HPV) infection of the anogenital tract, HPV E7 inactivates Rb resulting in increased p16 expression which can be diagnostically useful. The p16 protein is also increased in a variety of non-HPV-related neoplasms including esophageal squamous cell 20 and ovarian 21 carcinomas and osteosarcomas. 22 Presumably p16 has lost its tumor suppressive function in such cells intensity time the extent to yield scores from 0 to 9. Staining was evaluated in both cytoplasm and nucleus independently for p16. For ERG staining nuclear staining in cancer cells was scored using the same system.
| DNA extraction
Germline DNA was extracted from up to 25 mg of snap frozen seminal vesicle or benign prostate tissue using a DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD) using the manufacturers protocol. Table 1 . The AA patients were slightly younger (59.6 vs 61.2 years; P = 0.046, t test) and had significantly higher primary Gleason score (3.2 vs 3.0; P < 0.001). In addition, the total Gleason sum was higher in the AA patients (7.0 vs 6.8; P = 0.043). Of note, there was a highly significant increase in the proportion of AA patients with Grade group 3 (Gleason score 4 + 3 = 7)
| Genetic ancestry estimation
compared with EA patients (P < 0.001, χ AA, 33 our PCa specific death is very similar at 8 years of follow-up. This is in line with the overall low PCa specific mortality following radical prostatectomy in other cohorts. Our overall mortality was significantly lower than the PIVOT cohort (10% vs 20%). This may be due in part to the younger age of our patients (60 vs 67 years) as well as differences in patient selection for exclusion from radical prostatectomy based on comorbidities in the two cohorts.
Assignment of the race was based on the patient's self-reported race. We assessed the AIMs in the AA cases for which DNA was available after extraction from snap frozen benign tissue taken at the time of surgery. A total of 170 DNAs were analyzed. Mean West
African ancestry was 77.2 ± 0.1 (SD)%, 6 ± 0.04% Native American, and 16.8 ± 0. Table S1 . However, the cohort is relatively small and the clinical and pathological parameters do not show extensive variability since all patients were candidates for curative radical prostatectomy. In addition, more than 70% of AA men in our cohort fell between 70%
and 90% West African lineage. Thus, the amount of variation was small in our cohort, limiting our ability to examine associations.
Perhaps a much larger and/or more variable cohort might yield statistically significant associations.
| Expression of p16 in AA and EA benign prostate and PCa tissues
The TMAs were stained by IHC with clinical grade p16 antibody using our established protocol. Staining was then scored. Both cytoplasmic and nuclear staining of p16 was assessed in benign 
cases from AA men and 189 from EA men were evaluable in benign and/or PCa tissues. The intensity was scored from 0 to 3+, with 0 being absent staining, 1+ weak, 2+ moderate, and 3+ strong staining.
The extent of staining was also scored 0 to 3 based on the percentage of cells stained (0, <30%, 30%-60%, or >60% as 0-3, respectively). A multiplicative staining score calculated by multiplying intensity times extent yielding scores from 0 to 9. Scores of 7 to 9
were considered strong staining, 4 to 6 as moderate staining, and 1 to 3 as weak staining. Examples of staining in benign prostate and PCa are shown in Figure 1 . Both the intensity and extent of staining were quite variable in both groups and scores from 0 to 9 were seen across all groups. Cytoplasmic and nuclear staining scores were highly correlated within groups. Cytoplasmic and nuclear staining in benign tissues from AA and EA benign tissues had a correlation coefficient of r = 0.85 (P < 0.0001, Pearson Product Moment). Similar but slightly lower correlations were seen in cancer groups (r = 0.64 and 0.81 for AA and EA, respectively; Table 2 ). We also observed occasional staining of basal cells and spindle cells within the stroma, but these were not scored. Figure 3 , for EA PCa, p16 staining scores were significantly higher in both the cytoplasmic and nuclear compartments than the same compartment in benign tissue (P < 0.001, Mann Whitney). Cancer F I G U R E 3 Cytoplasmic and nuclear staining scores in AA and EA prostate cancer. Mean ± SEM of p16 cytoplasmic and nuclear staining is shown. Asterisks indicate statistically significant differences between benign and cancer within each racial group by the cellular compartment. ***P < 0.001 and *P < 0.05; ### Mann Whitney test's statistically significant difference (P < 0.001, Mann Whitney) between AA and EA benign tissues in both cellular compartments. AA, African American; EA, European American; IHC, immunohistochemistry scores in AA cancer tissues were also significantly higher in the nucleus (P < 0.001, Mann Whitney) and cytoplasm (P < 0.05, Mann Whitney) compared with benign tissues in tissues from AA men.
Consistent with prior reports, the EA benign tissues were only weakly or not stained for p16 protein except for one case which showed strong staining ( Figure 2) . Surprisingly, the AA benign tissues showed strong nuclear staining in 4% of cases and moderate staining in 13% of cases ( Figure 2) . Consistent with the observations described above, the AA benign tissue showed significantly stronger staining in both the nucleus and cytoplasm compared with EA benign tissues (P < 0.001, Mann Whitney; Figure 3 ). Of note, cytoplasmic and nuclear staining in benign tissues were strongly correlated with nuclear staining in cancer tissues in AA tissues (r = 0.38 and 0.49, respectively, both P < 0.001; Table 2 ). Examination of the heat map of staining scores in Figure 2 shows that 22 of 27 AA benign cases with strong or moderate staining in the cytoplasm and/or nuclei of benign cells had strong or moderate p16 staining in the cancer nuclei, consistent with the observed correlation described above. However, in tissues from EA patients, no correlation was seen between staining in cytoplasmic or nuclear staining in benign tissues and nuclear (or cytoplasmic) staining in cancer cells.
Overall these results indicate that p16 staining is significantly higher in AA benign tissues and this is associated with p16 nuclear expression in PCa tissues in these patients in many cases.
| Expression of p16 in AA benign prostate and PCa tissues is associated with a family history of PCa
We next examined the correlation of p16 with various clinical and pathological parameters in both AA and EA patients. We did not observe any association of p16 staining in nuclei or cytoplasm of benign or cancer tissues with age, body mass index, preoperative PSA, Gleason score, extracapsular extension, seminal vesicle invasion, pelvic lymph node metastasis, biochemical recurrence, or death from PCa or other causes (Table S2 ). However, we did find a significant correlation of family history of PCa in AA patients, with p16 expression in benign tissues and cytoplasmic staining in cancer (Table 3A) . Nuclear staining in cancer trended toward a positive correlation (P = 0.06). This is shown in the heatmaps in Figure 4 comparing p16 staining in AA benign and cancer tissues in patients with or without a family history of PCa. There is clearly a much higher percentage of cases with moderate to strong staining in prostates from men with a family history of PCa, particularly in cancer tissues. Based on this observation, we analyzed the proportion of cases with strong p16 staining in men with or without a family history of PCa. There was a significant association of family history of PCa with strong nuclear staining in benign tissues (Table 3B ).
| Increased p16 messenger RNA in PCa
The IHC studies above show that p16 protein is increased in both AA and EA PCa. This could be due to increased p16 messenger RNA (mRNA) or potentially to posttranscriptional factors such as increased translation, increased protein stability, and so forth. We, therefore, examined our previously published expression microarray data that examined gene expression in 48 AA PCa and benign tissues 10 for CDKN2A (p16 gene) expression. Expression was 1.2-fold higher in PCa (P = 0.009, t test) as shown in Figure 5A . We then examined CDKN2A expression in PCa datasets in Oncomine. Of 14 data sets with mRNA data, all from predominantly EA cohorts, 8 of 14 showed a statistically significant increase in CDKN2A (examples shown in Figure 5B -D) and only 1 of 14 showed a statistically significant decrease. Thus, the increased p16 protein expression in both AA and EA patients is due, at least in part, to increased p16 mRNA levels in the PCa tissues.
| Expression of ERG in AA and EA PCa tissues
The same set of TMAs was then stained with an anti-ERG antibody to evaluate the expression of the T/E fusion gene using IHC. We and others have shown that there is variability in the intensity and extent of ERG staining in PCa. 34 Therefore, the intensity was scored using the multiplicative staining index as described for p16 except only nuclear staining in cancers was scored. Scores of 7 to 9 were considered strong staining, 4 to 6 as moderate staining and 1 to 3 as weak staining. Data for both races is shown in Figure 6 . As expected, Bold values are statistically significant using indicated statistical tests.
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protein expression level is controlled at both the transcriptional and posttranscriptional level, but a detailed understanding of control in human PCa tissues is still lacking. There was also a significantly higher proportion of cases with no staining as expected (P < 0.05, χ 2 ).
The association of the variables in Table 1 Table 1 with ERG status in AA PCa was seen. The percent West African ancestry was also not associated with ERG status (Table S1 ).
| Expression of p16 is correlated with ERG status in AA PCa
Finally, we examined the correlation of p16 cytoplasmic and nuclear staining in cancer cells with ERG expression in AA PCa. Interestingly, there was a significant correlation of p16 staining with ERG staining.
Spearman Rank Order correlation for p16 cytoplasmic staining with ERG staining was r = 0.484 with P < 0.001 and for p16 nuclear staining was r = 0.259 with P < 0.01. The mean p16 nuclear staining in ERG-positive cases was significantly higher than in ERG-negative cases (4.69 vs 2.94; P < 0.001, Mann Whitney) as was cytoplasmic staining (4.91 vs 2.3; P < 0.001). No significant correlation was seen in EA PCa and there was no significant difference in the mean p16 nuclear or cytoplasmic staining in ERG positive and ERG negative cases from EA men.
| DISCUSSION
There have been multiple studies of p16 protein expression in EA and
European prostate and PCa cohorts by IHC. [23] [24] [25] [26] [27] [28] [29] To our knowledge ours is the only study of p16 protein expression in AA prostate tissue and PCa. In the EA and European cohorts, increased p16 protein in PCa compared with benign prostate has been a consistent finding.
The largest study was of a German cohort of 9627 PCas on TMAs. 23 Of note, this group found a strong association between the presence of the T/E fusion and associated ERG expression and p16 expression, although the exact mechanism of this association is unknown. AA PCa has a significantly lower incidence of the T/E fusion compared with EA PCa 12-17 and we have confirmed this in the current study. 25 this may be due in part to factors such as the IHC protocol, the scoring system, group choice for analysis and patient selection. In addition, the size of the cohort and the length of follow-up may impact whether such associations are seen, particularly if they are relatively weak. Examination of the very large cohort of Burdelski et al 23 suggests that p16 expression has an impact on the outcome, but mainly in the ERG negative cases within this European cohort. We did not see this association (data not shown) but our cohort is much smaller.
| CONCLUSIONS
While p16 expression in cancer tissues is similar in AA and EA PCa tissues, p16 expression is more strongly associated with ERG expression in AA men and is associated with increased p16 expression in benign tissues. These findings suggest significant differences in the Rb/p16 pathway in AA and EA that warrant further investigation.
